Literature DB >> 26930265

Attenuation of hyperglycemia-induced apoptotic signaling and anti-angiogenic milieu in cultured cytotrophoblast cells.

Chase Cawyer1, Syeda H Afroze2, Nathan Drever1, Steven Allen1, Richard Jones1, David C Zawieja2, Thomas Kuehl1,3, M Nasir Uddin1,3,4.   

Abstract

OBJECTIVE: Preeclampsia (preE) is a hypertensive disorder that occurs 20% in diabetic pregnancy. We have shown that hyperglycemia impairs cytotrophoblast cell (CTB) function. In this study, we assess apoptotic and anti-angiogenic signaling in excess glucose-induced CTBs. STUDY
DESIGN: Human extravillous CTBs (Sw. 71) were treated with 100, 150, 200, 300, or 400 mg/dL glucose for 48 h. Some cells were pretreated with a p38 inhibitor (SB203580) or a peroxisome proliferator-activated receptor gamma (PPARγ) ligand (rosiglitazone) or with D-mannitol. Cell lysates were utilized to measure p38 MAPK phosphorylation, PPARγ, Bcl-2-associated-X protein (Bax), anti-apoptotic Bcl-2, caspase-9, and cyclooxygenase-2 (Cox-2) expression by western blot. Levels of the vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), and interleukin 6 (IL-6) were measured in culture media using ELISA kits. Statistical comparisons were performed using analysis of variance with Duncan's post hoc test.
RESULTS: p38 phosphorylation and PPARγ were upregulated (p < 0.05) in CTBs treated with ≥150 mg/dL glucose compared to basal (100 mg/dL). Expressions of Bax/Bcl-2, Cox-2, and caspase-9 were upregulated (p < 0.05) in CTBs treated with ≥150 mg/dL glucose. Secretion of sFlt-1, sEng, and IL-6 was increased while VEGF and PIGF were decreased in CTB-treated ≥150 mg/dl of glucose (*p < 0.01 for each). SB203580 or rosiglitazone pretreatment significantly attenuated hyperglycemia-induced apoptotic and anti-angiogenic signaling. D-Mannitol had no effect.
CONCLUSION: Hyperglycemia induced apoptotic and anti-angiogenic signaling in CTBs. The observed diminution of hyperglycemia-induced signaling by SB203580 or rosiglitazone pretreatment suggests the involvement of apoptotic and anti-angiogenic signaling in CTB dysfunction.

Entities:  

Keywords:  Anti-angiogenic; apoptotic; cytotrophoblast cells; diabetes; preeclampsia; pregnancy

Mesh:

Substances:

Year:  2016        PMID: 26930265     DOI: 10.3109/10641955.2015.1122035

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  5 in total

1.  Rosiglitazone augments antioxidant response in the human trophoblast and prevents apoptosis†.

Authors:  Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Leena Kadam; Eugenia Johnson; Bradley L Kolb; Javier Rodriguez-Kovacs; Michael Hertz; D Randall Armant; Sascha Drewlo
Journal:  Biol Reprod       Date:  2019-02-01       Impact factor: 4.285

Review 2.  Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome.

Authors:  Matej Vicen; Ivone Cristina Igreja Sá; Katarína Tripská; Barbora Vitverová; Iveta Najmanová; Samira Eissazadeh; Stanislav Micuda; Petr Nachtigal
Journal:  Cell Mol Life Sci       Date:  2020-11-13       Impact factor: 9.261

3.  The Relationship between Angiogenic Factors and Energy Metabolism in Preeclampsia.

Authors:  Alejandra Abascal-Saiz; Marta Duque-Alcorta; Victoria Fioravantti; Eugenia Antolín; Eva Fuente-Luelmo; María Haro; María P Ramos-Álvarez; Germán Perdomo; José L Bartha
Journal:  Nutrients       Date:  2022-05-23       Impact factor: 6.706

4.  Effects of modified lipoproteins on human trophoblast cells: a role in pre-eclampsia in pregnancies complicated by diabetes.

Authors:  Rebecca Helen McLeese; Jiawu Zhao; Dongxu Fu; Jeremy Y Yu; Derek P Brazil; Timothy J Lyons
Journal:  BMJ Open Diabetes Res Care       Date:  2021-01

5.  Apoptotic and stress signaling markers are augmented in preeclamptic placenta and umbilical cord.

Authors:  Syeda H Afroze; Ram R Kalagiri; Michelle Reyes; Jacqueline D Zimmerman; Madhava R Beeram; Nathan Drever; David C Zawieja; Thomas J Kuehl; Mohammad N Uddin
Journal:  BBA Clin       Date:  2016-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.